Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SCHAUMBURG, Ill., July 31, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Docetaxel Injection Concentrate, an antineoplastic agent, in three preservative-free vial presentations. According to IMS, for the 12 months ending June 2013, the US market for Docetaxel Injection Concentrate approximated $412 million. As with all products in Sagent’s portfolio, Docetaxel features Sagent’s PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
Help employers find you! Check out all the jobs and post your resume
